Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Precision BioSciencesDTIL +0.60%45 3-Year EPS without NRI Growth Rate is 40.30% as of Jun. 2026, which is 12% above its 10-year median of 36.05. GuruFocus rates DTIL with a GF Score™ of 45/100 and a GF Value™ of $1.85 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,157 Biotechnology companies, Precision BioSciences ranks better than 77.79% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 40.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 44.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Precision BioSciences was 51.30% per year. The lowest was -49.70% per year. And the median was 36.05% per year.
Precision BioSciences (NAS:DTIL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Precision BioSciences 3-Year EPS without NRI Growth Rate Related Terms
DTIL vs NBP, PEPG, CHRS: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Precision BioSciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precision BioSciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Precision BioSciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Precision BioSciences's 3-Year EPS without NRI Growth Rate falls into.
Precision BioSciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 40.30% mean?
Precision BioSciences (DTIL) has a 3-Year EPS without NRI Growth Rate of 40.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Precision BioSciences and its competitors. This is 12% above median its historical median of 36.05. According to the industry distribution chart, Precision BioSciences ranks #257 out of 1157 companies in the Biotechnology industry, placing it in the top 22.2%.
Is Precision BioSciences' 3-Year EPS without NRI Growth Rate too high?
Precision BioSciences' current 3-Year EPS without NRI Growth Rate of 40.30% is 12% above median its 10-year median of 36.05. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. Precision BioSciences' value of 40.30% is 153.5% above this industry median. Based on the distribution chart, Precision BioSciences ranks #257 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Precision BioSciences has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Precision BioSciences' 3-Year EPS without NRI Growth Rate compare to NBP and PEPG?
According to the Biotechnology industry distribution chart, Precision BioSciences ranks #257 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places Precision BioSciences in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.90. Precision BioSciences' value of 40.30% is 153.5% above this benchmark. While the company's 10-year median is 36.05 vs. the industry median of 15.90, Precision BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Precision BioSciences's current 3-Year EPS without NRI Growth Rate of 40.30% is 153.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Precision BioSciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Precision BioSciences's current 3-Year EPS without NRI Growth Rate is 40.30%, which is 12% above median its own 10-year median of 36.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precision BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Precision BioSciences (DTIL) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.85, compared to a current price of $6.67 — trading 260.5% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 40.30%, which is 12% above median its 10-year median of 36.05 and 153.5% above the Biotechnology industry median of 15.90. Precision BioSciences' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Precision BioSciences (DTIL), the current 3-Year EPS without NRI Growth Rate is 40.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precision BioSciences (DTIL) Overvalued in 2026?
Based on GuruFocus' analysis, Precision BioSciences stock appears to be overvalued.
The current stock price of $6.67 is trading 260.5% above its estimated GF Value™ of $1.85.
GuruFocus considers Precision BioSciences to be Significantly Overvalued.
Key valuation signals for DTIL:
3-Year EPS without NRI Growth Rate: 40.30% (12% above median its 10-year median of 36.05)
GF Value™: $1.85 vs. price of $6.67 (260.5% above fair value)
Industry Position: 153.5% above the Biotechnology median (#257 of 1157)
No single metric tells the full story. See the DTIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
45GF Score
Get the complete analysis for DTIL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DTIL has been successfully added to your 
